Article Text

other Versions

PDF
Extended report
Mesenchymal stem cell therapy in proteoglycan induced arthritis
  1. J F Swart1,
  2. S de Roock1,
  3. F M Hofhuis2,
  4. H Rozemuller2,
  5. T van den Broek1,
  6. P Moerer2,
  7. F Broere3,
  8. F van Wijk1,
  9. W Kuis1,
  10. B J Prakken1,
  11. A C M Martens4,
  12. N M Wulffraat1
  1. 1Department of Pediatric Immunology and Laboratory of Translational Immunology, Center for Molecular and Cellular Intervention (CMCI), Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
  2. 2Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  3. 3Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
  4. 4Department of Cell Biology, University Medical Center Utrecht, Utrecht, The Netherlands
  1. Correspondence to Joost F Swart, Department of Pediatric Immunology and Laboratory of Translational Immunology, Center for Molecular and Cellular Intervention (CMCI), Wilhelmina Children's Hospital, University Medical Center Utrecht, KC 03.063.0, PO Box 85090, Utrecht 3508 AB, The Netherlands; jswart{at}umcutrecht.nl

Abstract

Objectives To explore the immunosuppressive effect and mechanism of action of intraperitoneal (ip) and intra-articular (ia) mesenchymal stem cell (MSC) injection in proteoglycan induced arthritis (PGIA).

Methods MSC were administered ip or ia after establishment of arthritis. We used serial bioluminescence imaging (BLI) to trace luciferase-transfected MSC. Mice were sacrificed at different time points to examine immunomodulatory changes in blood and secondary lymphoid organs.

Results Both ip and local ia MSC injection resulted in a beneficial clinical and histological effect on established PGIA. BLI showed that MSC ip and ia in arthritic mice are largely retained for several weeks in the peritoneal cavity or injected joint respectively, without signs of migration. Following MSC treatment pathogenic PG-specific IgG2a antibodies in serum decreased. The Th2 cytokine IL-4 was only upregulated in PG-stimulated lymphocytes from spleens in ip treated mice and in lymphocytes from draining lymph nodes in ia treated mice. An increase in production of IL-10 was seen with equal distribution. Although IFN-γ was also elevated, the IFN-γ/IL-4 ratio in MSC treated mice was opposite to the ratio in (untreated) active PGIA.

Conclusions MSC treatment, both ip and ia, suppresses PGIA, a non-collagen induced arthritis model. MSC are largely retained for weeks in the injection region. MSC treatment induced at the region of injection a deviation of PG-specific immune responses, suggesting a more regulatory phenotype with production of IL-4 and IL-10, but also of IFN-γ, and a systemic decrease of pathogenic PG-specific IgG2a antibodies. These findings underpin the potential of MSC treatment in resistant arthritis.

  • Rheumatoid Arthritis
  • DMARDs (biologic)
  • Treatment
  • Juvenile Idiopathic Arthritis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.